Microsoft word - api customer communication - english - final.doc
Dear Valued Customer: In 2010 Abbott completed the acquisition of Solvay Pharma Canada, Inc. (now known as Abbott Products Inc.). We are pleased to inform you that we are now fully integrating
all products and processes into Abbott’s product portfolio. If you have been purchasing products directly from Abbott in the past, the only change for you will be that you will now be able to purchase both Abbott and Abbott Products
Inc. products directly from Abbott. If you have been purchasing Abbott Products Inc. products from a wholesaler or distributor, through electronic data interchange (EDI) or through the CPDN network,
there will be changes to your ordering, returns and financial transactions. These changes are described in detail below.
Please share this information with all departments in your organization that will be
affected by these changes. Effective January 4, 2011, please place all orders directly with Abbott. Between now and January 4, please continue to place orders as you normally would, keeping the
following timeline in mind. Wednesday, December 22, 2010
The last day to place orders through Abbott Products Inc. Customer Service.
Orders placed with Abbott Products Inc. prior to 3:00 p.m. (EST) will be
processed and shipped in the usual manner.
No orders for Abbott Products Inc. products will be processed or shipped during
Abbott Products Inc. products will not be available through CPDN. Final orders
will be shipped from CPDN December 28, 2010.
All backorders with Abbott Products Inc. will be cancelled on December 23,
As of December 22, 2010 at 3 p.m. (EST), Abbott Products Inc. will no longer be
able to accept EDI transactions for product purchases.
Beginning January 4, 2011, your EDI group may begin including all products
with their normal communication to Abbott.
NARCOTIC & CONTROLLED DRUG ORDER PROCESSING: Effective January 4, 2011, for customers ordering narcotic/controlled drugs (other than in Newfoundland), please address scripts as follows:
Tel.: (905) 712-7234 Toll Free: 1-866-456-7770
Fax: 1-800-768-1976 For Newfoundland-based customers, please address scripts as follows: For Kadian and Ultiva products:
PRODUCTS LISTING: The attached product listing identifies the OLD Abbott Products Inc. product codes and the NEW Abbott product codes.
Effective January 4, 2011, the following payment terms will apply to all products
purchased from Abbott. Terms: Retail: 1% 15 days, Net 30, Hospitals and others: Net 30.
STANDARD TERMS AND CONDITIONS: The most current version of the Standard Terms and Conditions can be found on www.abbott.ca under Contact us/Customer Service/Ordering Information.
Abbott Products Inc. products will be affected by a change in return policy as follows:
As of January 4, 2011, Abbott’s return policy will take effect. This policy is consistent
with Abbott’s current Standard Terms and Conditions. Please note that Marinol and Influvac are non-eligible items for return. All other Abbott Products Inc. products will be
creditable up to six months post-expiry.
1. All qualified Abbott pharmaceutical products up to six months post-expiry are
eligible for a 100% credit. Expired part-bottles in their original container will be
2. All requests for authorization for the return of controlled drugs or narcotics must
be made to the servicing distribution centre’s Qualified Person In Charge (QPIC). All qualified Abbott controlled drugs and narcotics up to six months post-expiry
3. For credit to be issued, all returns must be approved by a customer service
representative prior to shipment. Products not purchased through Abbott directly should be returned to the point of purchase.
4. NON-ELIGIBLE ITEMS: The following merchandise is sold on a non-returnable
basis: Diagnostic products, Hydrasorb, Survanta, Norvir capsules, Kaletra
capsules and oral solution, Synagis, Humira, Calcijex, Lupron 14 days, Nimbex, Prevacid capsules, Prevacid FasTab, Marinol and Influvac.
(514) 832-7333 or 1-800-567-2226 Fax: 514-832-7251
INVOICE PAYMENTS, CREDIT & ACCOUNTS RECEIVABLE OPERATIONS:
Effective January 4, 2011, invoices for purchases of Abbott Products Inc. products will
reflect Abbott lockbox information. There are no changes to the Abbott lockbox addresses. You will receive combined invoices for Abbott and Abbott Products Inc.
products. All remittance and resolution will be handled by Abbott Accounts Receivable.
Invoices for shipments made by Abbott Products Inc. prior to January 4, 2011
should be paid to the Abbott Products Inc. lockbox.
December 22, 2010 will be the last day of operation for Abbott Products Inc.
Customer Relations and Accounts Receivable. Abbott will be responsible for resolution of claims and invoices for all Abbott Products Inc. receivables after this
(514) 832-7189 or 1-800-465-8242 ext. 7189 Fax: 514-832-7852
We are looking forward to continuing to provide you with the high levels of products and customer service that you have become accustomed to when partnering with Abbott –
a global, broad-based health care company devoted to the discovery, development, manufacturing and marketing of pharmaceuticals and medical products, including
nutritionals, devices and diagnostics. I would like to take this opportunity to wish you a happy and healthy holiday season and New Year. Thank you for your continued business.
Director, External Operations Abbott Laboratories, Limited
ABBOTT PRODUCTS INC. / PRODUITS ABBOTT (formerly/anciennement Solvay Pharma Inc. ) Product name Description Product number / Nom du produit Désignation Code de produit 01011902
2.5 g gel per unit dose packet / 2,5 g de gel
01011903
5.0 g gel per unit dose packet / 5,0 g de gel par sachet à dose unique
01023002
60 actuations of 1.25 g of gelUne pompe à dose mesurée, permettant 60actionnements, chacun délivrant 1,25 g de gel
0W314099 0W313099 0W124099 0W139702 0W138713 0W184010
inactivatedVaccin antigrippal, antigène de surface, inactivé
0W003751 0W202775 0W002775 0W039775 0W037775 0W151751 0W150751 0W541060 01063060 0W085702 0W086713 0W546722 0W451722 0W362722
† Registered Trademark used under license by Abbott Products Inc., Markham, ON L3R 0C9 ® Registered Trademark used under license by Abbott Products Inc., Markham, ON L3R 0C9 Lipidil † Registered Trademark Fournier Industrie et Santé S.A. Licensed use by Fournier Pharma Inc., Montréal, QC H3A 2R7 * Abbott Products Inc. acting as an agent for FOURNIER PHARMA INC.
† Marque déposée utilisée sous licence par Abbott Products Inc., Markham, ON, L3R 0C9 ® Marque déposée utilisée sous licence par Abbott Products Inc., Markham, ON, L3R 0C9 Lipidil † Marque déposée Fournier Industrie et Santé S.A., utilisée sous licence par Fournier Pharma Inc., Montréal, QC H3A 2R7 * Abbott Products Inc./Produits Abbott agissant en tant qu'agent pour FOURNIER PHARMA INC.
BUNDESVERFASSUNGSGERICHT - 2 BvR 633/11 - IM NAMEN DES VOLKES a) den Beschluss des Oberlandesgerichts Karlsruhe b) den Beschluss des Landgerichts Heidelberg § 8 Abs. 2 Satz 2 in Verbindung mit § 12 Abs. 1 Satz 1, § 15 Abs. 1 des baden-württembergischen Gesetzes über die Unterbringung psychisch Kranker (Unterbringungsgesetz - UBG) vom 2. Dezember 1991, GBl S. 794 hat das Bundes